Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Starpharma, AstraZeneca deal

    Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer, Drug delivery AstraZeneca received rights to use Starpharma's DEP dendrimer drug …

    Published on 4/14/2014
  • Strox Biopharmaceuticals, Xbiotech deal

    Strox Biopharmaceuticals LLC, Wellington, Fla. XBiotech Inc., Austin, Texas Business: Infectious XBiotech acquired Strox's patent estate for an undisclosed antibody therapy for methicillin-resistant Staphylococcus …

    Published on 4/14/2014
  • Tetra Discovery, Broad Institute of MIT and Harvard deal

    Tetra Discovery Partners LLC, Grand Rapids, Mich. Broad Institute of MIT and Harvard, Cambridge, Mass. Business: Neurology Tetra partnered with the institute's Stanley Center for Psychiatric Diseases to evaluate the …

    Published on 4/14/2014
  • AbCheck, Pierre Fabre deal

    AbCheck s.r.o., Plzen, Czech Republic Laboratoires Pierre Fabre S.A., Castres, France Business: Antibodies AbCheck will use its AbSieve discovery platform to discover antibodies against undisclosed targets from Pierre …

    Published on 4/7/2014
  • Acceleron, Celgene deal

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Hematology Orphan disease company Acceleron disclosed in an SEC filing that partner Celgene is increasing its …

    Published on 4/7/2014
  • Actavis, Aurobindo deal

    Actavis plc (NYSE:ACT), Dublin, Ireland Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804), Hyderabad, India Business: Generics Aurobindo completed its acquisition of Actavis' generics commercial operations in seven …

    Published on 4/7/2014
  • Almirall, InDex deal

    Almirall S.A. (Madrid:ALM), Barcelona, Spain InDex Pharmaceuticals AB, Stockholm, Sweden Business: Autoimmune InDex granted Almirall rights to develop and commercialize Kappaproct in Europe. InDex is eligible for up 20 …

    Published on 4/7/2014
  • Amgen, GlaxoSmithKline deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Musculoskeletal, Cancer Amgen and GlaxoSmithKline mutually agreed to end part of a 2009 deal under which …

    Published on 4/7/2014
  • Anavex, Israel Institute for Biological Research (IIBR) deal

    Anavex Life Sciences Corp. (OTSQB:AVXL), New York, N.Y. Israel Institute for Biological Research (IIBR), Ness-Ziona, Israel Business: Neurology IIBR's Life Science Research Israel Ltd. subsidiary granted Anavex …

    Published on 4/7/2014
  • Aptiv Solutions, ICON deal

    Aptiv Solutions, Reston, Va. ICON plc (NASDAQ:ICLR), Dublin, Ireland Business: Supply/Service ICON will acquire fellow CRO Aptiv Solutions for $143.5 million in cash. Aptiv Solutions designs and executes adaptive …

    Published on 4/7/2014
  • AQTIS Medical B.V., Sinclair IS Pharma deal

    AQTIS Medical B.V., Utrecht, the Netherlands Sinclair IS Pharma plc (LSE:SPH), London, U.K. Business: Dermatology Sinclair acquired AQTIS for 16.6 million ($22.8 million) up front in cash. AQTIS is also eligible for up …

    Published on 4/7/2014
  • Arch Biopartners, University of Cincinnati deal

    Arch Biopartners Inc. (CNSX:ACH), Toronto, Ontario University of Cincinnati, Cincinnati, Ohio Business: Infectious The university granted Arch a one-year option to exclusively license rights to U.S. Patent No. 8,557,300…

    Published on 4/7/2014
  • Asklepios, Baxter deal

    Asklepios BioPharmaceutical Inc., Chapel Hill, N.C. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Gene/Cell therapy, Hematology Baxter will acquire Asklepios' Chatham Therapeutics LLC affiliate for $70…

    Published on 4/7/2014
  • AstraZeneca, Medical Research Council (MRC) deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Medical Research Council (MRC), London, U.K. Business: High throughput screening AstraZeneca and the MRC are partnering to evaluate over 2 million AstraZeneca molecules …

    Published on 4/7/2014
  • AveXis, ReGenX deal

    AveXis Inc., Dallas, Texas ReGenX Biosciences LLC, Washington, D.C. Business: Neurology, Gene/Cell therapy ReGenX granted AveXis exclusive, worldwide rights to develop and commercialize products using ReGenX's NAV rAAV9…

    Published on 4/7/2014
  • BioAlliance, Daewoong Pharmaceutical deal

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Business: Infectious BioAlliance granted Daewoong exclusive rights to develop and commercialize …

    Published on 4/7/2014
  • BioMAS, Cosmo deal

    BioMAS Ltd., Jerusalem, Israel Cosmo Pharmaceuticals S.p.A., (SIX:COPN), Lainate, Italy Business: Drug delivery, Infectious Cosmo disclosed in its 2013 earnings that on March 11, 2014, BioMAS granted Cosmo worldwide …

    Published on 4/7/2014
  • Celgene, Forma Therapeutics deal

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Forma Therapeutics Holdings LLC, Watertown, Mass. Business: Pharmaceuticals Celgene and Forma partnered to discover and develop compounds targeting undisclosed protein families …

    Published on 4/7/2014
  • Charles River, Galapagos deal

    Charles River Laboratories International Inc. (NYSE:CRL), Wilmington, Mass. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Business: Supply/Service Charles River completed its acquisition of the Argenta …

    Published on 4/7/2014
  • Clinigen Group, Norgine, SpePharm deal

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Norgine B.V., Amsterdam, the Netherlands SpePharm Holding B.V., Amsterdam, the Netherlands Business: Musculoskeletal Clinigen will acquire from SpePharm AG - a 50/50 …

    Published on 4/7/2014
  • Convergence Pharmaceuticals Holdings, Evotec deal

    Convergence Pharmaceuticals Holdings Ltd., Cambridge, U.K. Evotec AG (Xetra:EVT), Hamburg, Germany Business: Neurology Evotec and Convergence's Panion Ltd. subsidiary partnered to develop analgesics to treat chronic …

    Published on 4/7/2014
  • Debiopharm, Evotec deal

    Debiopharm Group, Lausanne, Switzerland Evotec AG (Xetra:EVT), Hamburg, Germany Business: Cancer Evotec partnered with Debiopharm to discover and develop compounds against cancers with known genetic alterations, …

    Published on 4/7/2014
  • Eisai, Otsuka Pharmaceutical deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Cancer Otsuka acquired from Eisai full rights to Dacogen decitabine in the U.S., Canada and Japan and now owns full …

    Published on 4/7/2014
  • Epigenetix, Neomed Institute deal

    Epigenetix Inc., Miami, Fla. Neomed Institute, Montreal, Quebec Business: Cancer Not-for-profit life sciences research center Neomed and Epigenetix partnered to develop bromodomain containing 4 (BRD4) inhibitors as an …

    Published on 4/7/2014
  • J&J, The Carlyle Group deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. The Carlyle Group, Washington, D.C. Business: Diagnostic Johnson & Johnson accepted a binding offer from asset manager The Carlyle Group to acquire the pharma's Ortho-…

    Published on 4/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993